Denopamine

Denopamine

SCHEMBL218640

COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 12/20 1.00
ADRB1 P08588 8/20 1.00
LMNA P02545 2/20 1.00
SLC6A4 P31645 2/20 1.00
SLC6A3 Q01959 2/20 1.00
ALDH1A1 P00352 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
SLC22A1 O15245 1/20 1.00
CHRM2 P08172 1/20 1.00
CYP3A4 P08684 1/20 1.00
CHRM1 P11229 1/20 1.00
TSHR P16473 1/20 1.00
NFKB1 P19838 1/20 1.00
OPRM1 P35372 1/20 1.00
HIF1A Q16665 1/20 1.00
ADRB3 P13945 7/20 0.66
DRD2 P14416 2/20 0.60
DRD1 P21728 2/20 0.60
DRD4 P21917 2/20 0.60
DRD3 P35462 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Denopamine SCHEMBL218641 1.00 ADRB2 (1.00) ADRB2ADRB1LMNASLC6A4SLC6A3
Denopamine SCHEMBL4542605 1.00 ADRB2 (1.00) ADRB2ADRB1LMNASLC6A4SLC6A3
Denopamine SCHEMBL29964546 1.00 ADRB2 (1.00) ADRB2ADRB1LMNASLC6A4SLC6A3
Denopamine SCHEMBL7338329 0.99 ADRB2 (0.97) ADRB2ADRB1LMNASLC6A4SLC6A3
SCHEMBL11545733 0.90 ADRB2 (0.81) ADRB2ADRB1LMNASLC6A4SLC6A3
SCHEMBL11710152 0.90 ADRB2 (0.81) ADRB2ADRB1LMNASLC6A4SLC6A3
SCHEMBL11805204 0.90 ADRB2 (0.81) ADRB2ADRB1LMNASLC6A4SLC6A3
Hydrochloric Acid SCHEMBL11804583 0.89 ADRB2 (0.80) ADRB2ADRB1LMNASLC6A4SLC6A3
SCHEMBL11257835 0.88 ADRB2 (1.00) ADRB2ADRB1LMNASLC6A4SLC6A3
Hydrochloric Acid SCHEMBL11710346 0.88 ADRB2 (0.78) ADRB2ADRB1LMNASLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2187 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025265094-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-26 WO claimed
US-20250228824-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF ITO AS TREATMENT FOR THE J WAVE SYNDROMES AND HYPOTHERMIA SIMON FRASER UNIVERSITY (CA) 2025-07-17 US claimed
CN-119233997-A Tetrahedral antibodies 生物分子控股有限责任公司 2024-12-31 CN claimed
US-20240398729-A1 Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders DUKE UNIVERSITY (US) 2024-12-05 US claimed
EP-4463485-A2 TETRAHEDRAL ANTIBODIES Biomolecular Holdings LLC (US) 2024-11-20 EP claimed
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-07 US claimed
US-20240301022-A1 GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF UNIV ASTON (GB) 2024-09-12 US claimed
WO-2023137373-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-20 WO claimed
WO-2023137387-A2 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-20 WO claimed
US-20230220115-A1 TETRAHEDRAL ANTIBODIES BIOMOLECULAR HOLDINGS LLC (US) 2023-07-13 US claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1725226-A2 THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN USING BETA-AMINOALCOHOLS Sosei R&D Ltd. (GB) 2006-11-29 EP claimed
WO-2005089741-A2 THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN USING BETA-AMINOALCOHOLS SOSEI R&D LTD. (GB) 2005-09-29 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
US-5693337-A OIL IN WATER EMULSION CONTAINING DRUG, LECITHIN, CITRIC ACID, AND METHIONINE, PHENYLALANINE, SERINE, AND/OR HISTIDINE; SYNERGISTIC, STORAGE STABILITY WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) 1997-12-02 US claimed
EP-0700678-A1 Stable lipid emulsion Wakamoto Pharmaceutical Co., Ltd. (JP) 1996-03-13 EP claimed